Eric Morand, C. Arriens, L. Geraldino-Pardilla, Ann E Clarke, S. Pomponi, C. Hobar, Thomas L. Wegman, Ravi Koti, Subhashis Banerjee, R. V. Vollenhoven
{"title":"O32 在系统性红斑狼疮的 PAISLEY 试验 2 期中,患者基线特征对系统性红斑狼疮应答者指数-4 (SRI[4]) 对 deucravacitinib(一种首创的口服选择性异位酪氨酸激酶 2 抑制剂)应答的影响","authors":"Eric Morand, C. Arriens, L. Geraldino-Pardilla, Ann E Clarke, S. Pomponi, C. Hobar, Thomas L. Wegman, Ravi Koti, Subhashis Banerjee, R. V. Vollenhoven","doi":"10.1136/lupus-2024-el.41","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":517941,"journal":{"name":"Oral Presentations","volume":"9 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"O32 Impact of patient baseline characteristics on SLE Responder Index-4 (SRI[4]) responses to deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor in the phase 2 PAISLEY trial in systemic lupus erythematosus\",\"authors\":\"Eric Morand, C. Arriens, L. Geraldino-Pardilla, Ann E Clarke, S. Pomponi, C. Hobar, Thomas L. Wegman, Ravi Koti, Subhashis Banerjee, R. V. Vollenhoven\",\"doi\":\"10.1136/lupus-2024-el.41\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":517941,\"journal\":{\"name\":\"Oral Presentations\",\"volume\":\"9 4\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral Presentations\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/lupus-2024-el.41\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Presentations","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/lupus-2024-el.41","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
O32 Impact of patient baseline characteristics on SLE Responder Index-4 (SRI[4]) responses to deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor in the phase 2 PAISLEY trial in systemic lupus erythematosus